News and Trends 8 Jun 2023
Kate Therapeutics launches with $51M to develop genetic medicines for muscle and heart diseases
…worldwide license to develop, manufacture and commercialize KT430 to treat X-linked myotubular myopathy (XLMTM). There are a large number of genetically defined and complex muscle and heart diseases that cannot…